Latest & greatest articles for lamotrigine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lamotrigine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lamotrigine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lamotrigine

1. Lamotrigine is not effective for the treatment of borderline personality disorder

Lamotrigine is not effective for the treatment of borderline personality disorder Lamotrigine is not effective for the treatment of borderline personality disorder Dissemination Centre Discover Portal NIHR DC Discover Lamotrigine is not effective for the treatment of borderline personality disorder Published on 17 July 2018 doi: Lamotrigine, a mood-stabilising drug, is not clinically effective for the treatment of borderline personality disorder. Over one year follow up, this NIHR-funded trial (...) did not find a difference between lamotrigine and placebo for borderline personality disorder-related symptoms and behavioural problems, depressive symptoms, self-harm, social functioning or quality of life outcomes. Borderline personality disorder is a severe mental health disorder characterised by rapid and distressing fluctuations in mood, impaired social functioning and increased suicidal behaviour. Since emotional instability is a key clinical feature, it was thought treatments that help

NIHR Dissemination Centre2018

2. Lamotrigine

Lamotrigine Top results for lamotrigine - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lamotrigine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

3. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. BACKGROUND: This is an updated version of the original Cochrane Review published in Issue 11, 2006 of the Cochrane Database of Systematic Reviews.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential (...) to become seizure-free, and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug (AED) in monotherapy.The correct choice of first-line AED for individuals with newly diagnosed seizures is of great importance. It is important that the choice of AEDs for an individual is made using the highest quality evidence regarding the potential benefits and harms of the various treatments.Carbamazepine or lamotrigine are recommended as first-line treatments for new

Cochrane2018

4. Lamotrigine for people with borderline personality disorder: a RCT

Lamotrigine for people with borderline personality disorder: a RCT Lamotrigine for people with borderline personality disorder: a RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title (...) }} {{metadata.Headline}} Lamotrigine did not improve the symptoms of borderline personality disorder at 12 months. {{author}} {{($index , , , , , , , , , , , , , , , , , & . Mike J Crawford 1, * , Rahil Sanatinia 1 , Barbara Barrett 2 , Gillian Cunningham 3 , Oliver Dale 4 , Poushali Ganguli 2 , Geoff Lawrence-Smith 5 , Verity C Leeson 1 , Fenella Lemonsky 1 , Georgia Lykomitrou-Matthews 6 , Alan Montgomery 7 , Richard Morriss 7 , Jasna Munjiza 8 , Carol Paton 5 , Iwona Skorodzien 6 , Vineet Singh 9 , Wei Tan 7

NIHR HTA programme2018

5. Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review

Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review 29034101 2018 11 13 2056-4724 3 5 2017 Sep BJPsych open BJPsych Open Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review. 249-253 10.1192/bjpo.bp.117.005538 Optimal anti-epileptic drug (AED) treatment maximises therapeutic response and minimises adverse effects (AEs). Key to therapeutic AED treatment is adherence. Non-adherence is often related to severity (...) of AEs. Frequently, patients do not spontaneously report, and clinicians do not specifically query, critical AEs that lead to non-adherence, including sexual dysfunction. Sexual dysfunction prevalence in patients with epilepsy ranges from 40 to 70%, often related to AEDs, epilepsy or mood states. This case reports lamotrigine-induced sexual dysfunction leading to periodic non-adherence. To report lamotrigine-induced sexual dysfunction leading to periodic lamotrigine non-adherence in the context

BJPsych open2017 Full Text: Link to full Text with Trip Pro

6. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. BACKGROUND: This is an updated version of the original Cochrane review originally published in 2003, Issue 3, and updated in 2005, Issue 4.Absence seizures are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences (...) are characterised by sudden loss of awareness and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with typical absence seizures. OBJECTIVES: To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when

Cochrane2017

7. Lamotrigine

Lamotrigine USE OF LAMOTRIGINE IN PREGNANCY 0344 892 0909 USE OF LAMOTRIGINE IN PREGNANCY (Date of issue: December 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Lamotrigine is an anticonvulsant used either as sole treatment (...) or as adjunctive treatment of focal and generalized seizures, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Lamotrigine is also used in the treatment of bipolar disorder. There is no evidence from studies of over 7,500 exposed pregnancies that use of lamotrigine in the first trimester increases the overall risk of birth defects in the offspring. Although a possible association between first trimester lamotrigine use and orofacial clefting in the infant has been

UK Teratology Information Service2014

8. Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures.

Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. BACKGROUND: Primary generalized tonic-clonic seizures are one of a number of generalized seizure types which also includes absence, myoclonic and atonic seizures. Effective control of tonic-clonic seizures is required to reduce the risk of injury and death and to improve quality of life. While most people achieve seizure control with one antiepileptic drug, around 30% do not and usually take a combination (...) of antiepileptic drugs. OBJECTIVES: To assess the effectiveness of adjunctive lamotrigine for refractory primary generalized tonic-clonic seizures. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE (Ovid) 1950 to June 2010. No language restrictions were imposed. We also contacted GlaxoSmithKline, manufacturers of lamotrigine. SELECTION CRITERIA: Randomised parallel or cross-over add-on trials of add

Cochrane2010

9. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text

Evidence-Based Mental Health2010

10. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom

Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Verdian L, Yi Y Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of the addition of rufinamide compared with topiramate or lamotrigine for children with Lennox-Gastaut Syndrome that was uncontrolled by up to three traditional

NHS Economic Evaluation Database.2010

11. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD) Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD) Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD) Thomas SP, Nandhra HS, Jayaraman A CRD summary This review found there was little evidence on the use of lamotrigine for adults with depression who had not responded to a course of anti-depressants. The authors (...) ' conclusions appeared to reflect the lack of evidence available, but their reliability is unclear given the small number of included studies with small sample sizes and lack of reporting on study quality. Authors' objectives To assess the effectiveness of lamotrigine for patients with treatment-resistant depression. Searching The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, Cochrane Central Clinical trials Register (CENTRAL), PubMed, EMBASE, CINAHL and PsycINFO were

DARE.2010

12. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. 20200383 2010 03 04 2010 03 09 2016 12 15 1533-4406 362 9 2010 Mar 04 The New England journal of medicine N. Engl. J. Med. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. 790-9 10.1056/NEJMoa0902014 Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical (...) treatment has not been defined. In a double-blind, randomized, controlled clinical trial, we compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children with newly diagnosed childhood absence epilepsy. Drug doses were incrementally increased until the child was free of seizures, the maximal allowable or highest tolerable dose was reached, or a criterion indicating treatment failure was met. The primary outcome was freedom from treatment

NEJM2010 Full Text: Link to full Text with Trip Pro

13. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials 19118318 2009 01 01 2009 02 05 2016 11 22 1472-1465 194 1 2009 Jan The British journal of psychiatry : the journal of mental science Br J Psychiatry Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. 4-9 10.1192/bjp.bp.107.048504 (...) There is uncertainty about the efficacy of lamotrigine in bipolar depressive episodes. To synthesise the evidence for the efficacy of lamotrigine in bipolar depressive episodes. Systematic review and meta-analysis of individual patient data from randomised controlled trials comparing lamotrigine with placebo. Individual data from 1072 participants from five randomised controlled trials were obtained. More individuals treated with lamotrigine than placebo responded to treatment on both the Hamilton Rating Scale

EvidenceUpdates2009

14. Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia

Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Article Text Therapeutics Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Statistics from Altmetric.com No Altmetric data available for this article. Question Question: Is lamotrigine an effective

Evidence-Based Mental Health2009

15. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis Tiihonen J, Wahlbeck K, Kiviniemi V CRD summary This review concluded that lamotrigine augmentation may be an effective treatment for patients with clozapine-resistant schizophrenia (...) . The conclusions were appropriately cautious, but there were some limitations in the reporting of review methods and study details. Authors' objectives To assess the efficacy and safety of lamotrigine for the treatment of clozapine-resistant schizophrenia. Searching The database of the Cochrane schizophrenia group was searched without year or language limits. This includes searches of journals and conference proceedings and the following databases: BIOSIS Inside, Cochrane Central Register of Controlled Trials

DARE.2009

16. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Geddes JR, Calabrese JR, Goodwin GM CRD summary (...) This meta-analysis assessed the efficacy of lamotrigine in patients with acute bipolar depression. The authors concluded that it could be effective for treatment and for the prevention of relapse. This conclusion reflected the evidence presented, but the potential for error and bias throughout the review means that the reliability of this conclusion is unclear. Authors' objectives To assess the efficacy of lamotrigine in patients with acute bipolar depression. Searching In addition to the initial

DARE.2009

17. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine

Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Article Text Therapeutics Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Statistics from

Evidence-Based Mental Health2008

18. Lamotrigine for acute and chronic pain.

Lamotrigine for acute and chronic pain. BACKGROUND: Anticonvulsant medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This review looks at the evidence for the pain relieving properties of lamotrigine. OBJECTIVES: To assess the analgesic efficacy and adverse effects of the anticonvulsant lamotrigine for acute and chronic pain. SEARCH STRATEGY: Randomised Controlled Trials (RCTs) of lamotrigine (and key brand names Lamictal, Lamictin, Neurium) in acute (...) , chronic or cancer pain were identified from MEDLINE (1966 to August 2006), EMBASE 1994 to August 2006 and the CENTRAL register on The Cochrane Library (Issue 3, 2006). Additional reports were sought from the reference list of the retrieved papers. SELECTION CRITERIA: RCTs investigating the use of lamotrigine (any dose and by any route) for treatment of acute or chronic pain. Assessment of pain intensity or pain relief, or both, using validated scales. Participants were adults aged 18 and over. Only

Cochrane2007

19. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial Marson A G, Al (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed valproate, lamotrigine and topiramate. Drug dosages and preparations were used as the clinician would use them in everyday practice. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients with suspected epilepsy. Patients were included if they "had a history of two or more clinically definite

NHS Economic Evaluation Database.2007

20. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed five antiepileptic drugs. These were carbamazepine, gabapentin, lamotrigine, oxcarbazepine and topiramate. The drug dosages and preparations were used as they would be by a clinician in everyday practice. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

NHS Economic Evaluation Database.2007